Cytokine Storm, Covid-19, Influenza, Biotechnology

IN THE NEWS

NEWS RELEASE CYTOAGENTS RECEIVES FUNDING TO ACCELERATE COVID-19 CLINICAL TRIALS FOR CYTOKINE STORM TREATMENT FROM RICHARD KING MELLON FOUNDATION

Pittsburgh July 7, 2020

CytoAgents, a clinical-stage biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases, including COVID-19 and the resulting cytokine storm, announced today that it has received an investment to accelerate the development of its lead drug candidate, GP1681, an investigational new drug to treat “cytokine storm” induced by COVID-19, from the Richard King Mellon Foundation. Read More

CYTOAGENTS RECEIVES FUNDING TO ACCELERATE COVID-19 CLINICAL TRIALS FOR CYTOKINE STORM TREATMENT FROM RICHARD KING MELLON FOUNDATION

Yahoo Finance July 7, 2020

CYTOAGENTS GETS NIH FUNDING TO ADVANCE THERAPY FOR CYTOKINE STORM

Pharmaceutical Technology May 14, 2020

CYTOAGENTS RECEIVES NIH FUNDING TO ACCELERATE TREATMENT FOR CYTOKINE STORM

Boston Harbor Angels May 14, 2020

PITTSBURGH BIOTECH COMPANY RECEIVES $1.6 MILLION GRANT TO DEVELOP DRUG TO TREAT COVID-19

Pittsburgh Action News 4 May 14, 2020

NEWS RELEASE CYTOAGENTS RECEIVES NIH FUNDING TO ACCELERATE TREATMENT FOR CYTOKINE STORM

Pittsburgh May 13, 2020

CytoAgents, a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases, announced today that it has been awarded a National Institutes of Health (NIH) grant to accelerate the development of its lead drug candidate, GP1681, an investigational new drug to treat severe influenza, and potentially COVID-19, by targeting hypercytokinemia, more commonly known as “cytokine storm.” Read More

PITTSBURGH BIOTECH FIRM WINS NIH GRANT FOR COVID-19 CLINICAL TRIAL

Pittsburgh Business Times May 13, 2020

NORTH SHORE COMPANY GETS $1.6 MILLION GRANT FOR NEW DRUG DEVELOPMENT

Pittsburgh Post-Gazette May 13, 2020

PITTSBURGH HAS LONG BEEN A LIFE SCIENCES ENGINE. NOW IT’S AT THE FOREFRONT OF COVID-19 VACCINE EFFORTS

Technical.ly Media May 13, 2020

QUOTIENT SCIENCES, CYTOAGENTS FORM COVID-19 COLLABORATION

Contract Pharma May 4, 2020

NEWS RELEASE QUOTIENT SCIENCES AND CYTOAGENTS ACCELERATE POTENTIAL TREATMENT FOR COVID-19 CYTOKINE STORM

Nottingham, U.K., and Pittsburgh April 28, 2020

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases. Read More

© 2020 by CytoAgents

  • LI-In-Bug